Slide 1: 10M2025 Business Updates
10M2025 BUSINESS UPDATES IMEXPHARM CORPORATION
Slide 2: A strong October driven by OTC channel
A strong October driven by OTC channel ▪ OTC customers resumed stocking after several October net revenue months of low purchasing activity, driving VND 211 bn strong October performance with 18% MoM growth, equivalent to 81% YoY growth on the ▲ 20 % YoY ETC 1% YoY (*) back of this year’s strong rec
Slide 3: Profitability rose sharply on strong revenue growth and tighter cost management
Profitability rose sharply on strong revenue growth and tighter cost management 10M net revenue ▪ We are tracking 80% of gross revenue, 76% VND 2,011 bn of net revenue, and 73% of PBT and ▲ 16% YoY EBITDA toward the year-end targets. ETC ▲ 19% YoY (*) ▪ Among the four factories, IMP4 delivered the s
Slide 4: Business highlights
Business highlights Dr. Le Van Nha Phuong, PhD - Deputy CEO, delivered a Imexpharm accompanied the Ho Chi Minh City Respiratory thematic presentation on Imexpharm’s breakthrough in Orally Society and Children’s Hospital 1 in organizing the conference Disintegrating Tablet (ODT) formulation technolog
Slide 5: Recognized with prestigious awards in 10M2025
Recognized with prestigious awards in 10M2025 5
Slide 6: Stock performance
Stock performance % 160 IMP stock price 120 Weighted avg share price of top 6 pharma companies by 80 revenue 40 VNIndex 0 -40 IMP DHG TRA DHT DBD DMC YTD avg. daily trading volume 172,120 21,577 4,052 27,022 247,341 7,878 YTD stock performance 8% 8% (10%) (20%) (5%) (10%) Daily trading volume in 10M
Slide 7: Disclaimer
Disclaimer The contents of the IR Newsletter are intended to provide information to institutional investors as well as individual investors of Imexpharm Corporation (Hose: IMP). IMP strives to ensure transparency, completeness, and accuracy of the information in this newsletter. IMP is exempt from a
Slide 8: Thank You
Thank You For further discussion, please contact our IR team ir@imexpharm.com 8